The FDA on Wednesday approved Eli Lilly’s new daily oral GLP-1 weight-loss pill, Foundayo — with out-of-pocket monthly prices expected to range from about $149 to $349 and average weight loss of 12.4% at the highest dose after 72 weeks. Clinically, it adds a simpler, no-meal-restrictions option vs. Novo Nordisk’s Wegovy pill, but likely with less weight loss than injectable Wegovy or Zepbound.

The Move

• FDA approved Lilly’s Foundayo, a once-daily oral GLP-1 for weight loss.

• It’s the second oral GLP-1 to hit the market recently, after Novo Nordisk’s Wegovy pill (approved in December).

• Foundayo comes in six doses; patients typically titrate up to reduce side effects.

• Administration: can be taken any time of day without meal restrictions (unlike the Wegovy pill, taken on an empty stomach each morning).

Why it Matters for Care

• Expected cash price: about $149/month at the lowest dose; up to $349/month at higher doses — a practical access lever for patients paying out of pocket.

• Phase 3 data: 12.4% average weight loss at the highest dose at 72 weeks (not a head-to-head comparison with injectables).

• Use cases clinicians may see: patients who struggle with injections, those with injection-site reactions, and patients looking to maintain weight loss after injectable GLP-1s.

• Side effects appear similar to injectable GLP-1s: GI issues (nausea, constipation, diarrhea) most commonly reported.

Between the Lines

• Convenience is the selling point: no refrigeration/needle logistics and easier daily routine adherence — but efficacy may lag weekly injections, which could shape patient expectations and persistence.

• Coverage is the wild card: it’s unclear how many private insurers will cover Foundayo, keeping clinicians in the prior auth/step-therapy crossfire.

• Politics meets prescribing: a Trump administration plan could allow Medicare coverage for some patients as soon as this summer, with copays as low as $50/month — potentially shifting demand and formulary negotiations quickly.

• Market pressure is rising: Lilly is also developing retatrutide, which has shown greater weight loss in trials than current options, raising the odds of rapid therapeutic churn.

What to Watch

• Payer decisions: whether major commercial plans cover Foundayo, and what step edits require (e.g., injection first, BMI thresholds, comorbidity requirements).

• Medicare timeline: details and implementation of the Trump administration plan, including which indications/patient groups qualify and when coverage starts.

• Real-world outcomes: whether patients replicate ~12% weight loss on pills and how often clinicians use pills for maintenance after injectables.

• Next entrants: progress and regulatory milestones for higher-efficacy next-gen agents (including Lilly’s retatrutide) that could reset expectations on weight loss and pricing.

Source: NBC News Health